Sean Brynjelsen

Chief Executive Officer chez ETON PHARMACEUTICALS, INC.

Fortune : 4 M $ au 31/03/2024

52 ans

Health Technology

Consumer Services

Postes actifs de Sean Brynjelsen

Sociétés	Poste	Début	Fin
ETON PHARMACEUTICALS, INC.	Director/Board Member	01/06/2017	-
	Chief Executive Officer	01/06/2017	-
	President	01/06/2017	-

Sociétés	Poste	Début	Fin
SAGENT PHARMACEUTICALS INC	Corporate Officer/Principal	23/03/2016	01/06/2017
AKORN, INC.	Chief Tech/Sci/R&D Officer	18/06/2010	07/02/2014
AKORN, INC.	Corporate Officer/Principal	07/02/2014	01/03/2016

University of Notre Dame	Masters Business Admin
University of Illinois	Graduate Degree

Internationale

Etats-Unis

Opérationnelle

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Masters Business Admin	1

Sectorielle

Health Technology	4
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
ETON PHARMACEUTICALS, INC.	Health Technology

Entreprise privées	2
Akorn, Inc. Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL.	Health Technology
Sagent Pharmaceuticals, Inc. Sagent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sagent Pharmaceuticals, Inc. engages in the developing, manufacturing, and marketing of medical products. It offers injectable products such as amikacin sulfate, ampicillin and sulbactam, cefazolin, piperacillin and tazobactam, and vancomycin hydrochloride. The company was founded by Jeffrey M. Yordon in 2006 and is headquartered in Schaumburg, IL.	Health Technology

Entreprise privées

Health Technology